Dataset Information

Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres.

ABSTRACT: To gain an understanding of the efficacy of vedolizumab in a 'real-world' setting.Retrospective cohort study using prospectively maintained clinical records.Two UK tertiary inflammatory bowel disease (IBD) centres.Patients with IBD commenced on vedolizumab at Guy's & St Thomas' and King's College Hospitals during November 2014-November 2015.Vedolizumab, a monoclonal antibody to ?-4 ?-7 integrins that selectively inhibit leucocyte migration into the gut.Clinical disease activity was assessed at baseline, weeks 14 and 30 using Harvey-Bradshaw Index (HBI) for Crohn's disease (CD) and Simple Clinical Colitis Activity Index (SCCAI) for ulcerative colitis (UC). Response was defined as HBI or SCCAI reduction ?3. Remission was defined as HBI <5 or SCCAI <3. Continuous data are summarised as medians, followed by range.Fifty patients were included: 27 CD, 20 UC and 3 IBD-U (included in the UC group for analysis). At baseline visit, the median HBI was 8 (1-16) and SCCAI was 6 (0-15). At week 14, these values had fallen to 5 (0-15) (p=0.117) and 4 (0-10) (p=0.005), respectively. Additionally, week 30 data were available for 19 patients (9 CD, 10 UC). The clinical disease activity scores at that point were HBI 2 (0-7) (p=0.039) and SCCAI 2 (0-10) (p=0.023). At baseline, 37 (74%) of the 50 patients had clinically active disease. Of the patients with active disease, 22 (59%) responded and 14 (38%) achieved remission at week 14.Our early experience with vedolizumab demonstrates a clear benefit in terms of disease control as well as a steroid-sparing effect in a cohort, which included patients with complex and previously refractory disease.

SUBMITTER: Samaan MA

PROVIDER: S-EPMC5558276 | biostudies-other | 2017 Jul

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres.

Samaan Mark A MA Pavlidis Polychronis P Johnston Emma E Warner Ben B Digby-Bell Jonathan J Koumoutsos Ioannis I Fong Steven S Goldberg Rimma R Patel Kamal K Gulati Shraddha S Medcalf Lucy L Sastrillo Marlene M Brown-Clarke Cordella C Bidewell-Sullivan Johanna J Forsyth Katrina K Lee Emma E Stanton Anna A Duncan Julie J Chung-Faye Guy G Dubois Patrick P Powell Nick N Anderson Simon S Sanderson Jeremy J Hayee Bu'Hussain B Irving Peter M PM

Frontline gastroenterology 20160810 3

<h4>Objective</h4>To gain an understanding of the efficacy of vedolizumab in a 'real-world' setting.<h4>Design</h4>Retrospective cohort study using prospectively maintained clinical records.<h4>Setting</h4>Two UK tertiary inflammatory bowel disease (IBD) centres.<h4>Patients</h4>Patients with IBD commenced on vedolizumab at Guy's & St Thomas' and King's College Hospitals during November 2014-November 2015.<h4>Intervention</h4>Vedolizumab, a monoclonal antibody to α-4 β-7 integrins that selective ...[more]

PMID: 28839909

Similar Datasets

Project description:BackgroundGP led walk-in centres were established in the UK in 2009. Around 150 such clinics were initially planned to open. Their purpose is to provide a primary health care service to complement the urgent care services provided by Emergency Departments (ED), to reduce unnecessary patient attendance at ED, and to increase accessibility of health care services. The objectives of this study were to determine patient satisfaction and experiences with GP led walk-in centres in the UK.MethodsA survey was conducted in two GP led walk-in centres in the North of England over three weeks during September and October 2011. A self reported, validated questionnaire was used to survey patients presenting at these centres. A short post visit questionnaire was also sent to those who agreed. Ethical approval for the study was obtained from an NHS ethical review committee.ResultsBased on a sample of 1030 survey participants (Centre A = 501; Centre B = 529), we found that 93% of patients were either highly or fairly satisfied with the service at centre A and 86% at centre B. The difference between centres was due to the longer reported waiting times which were seen in centre B. There was no difference in satisfaction between first time users and repeat users (P value = 0.8). Roughly 50% (n = 507) of patients reported that their reason for using the walk-in centre was having GP access without an appointment, and 9% (n = 87) reported that their GP surgery was closed. A further 20% of patients (n = 205) reported that they were not able to see their own GP because of their working hours.In the post visit survey (n = 258), nearly all patients reported complying with the advice given (around 90% at both study centres), and most of the patients (86%) reported their problem had resolved a few days later. In addition, 56% of patients at centre B and 58% at centre A reported that they had also visited another NHS service for the same problem, mostly their own GP (66%).ConclusionsThe GP led walk-in centres increased access to GP care and most of the patients were satisfied with the service.

Dataset Information

Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres.

Publications

Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets